Cardiovascular outcomes among sildenafil users: Results of the International Men's Health Study

International Journal of Clinical Practice

Volumn 62, Issue 3, 2008, Pages 367-373

  Mittleman, M A ^a,b,c   MacLure, M ^c,d,e   Lewis, M A ^f   Hall, G C ^g   Moore, N ^h   Giuliano, F ⁱ   Porst, H ^j   Hedelin, H ^k   Martin Morales, A ^l   Sobel, R E ^m   Reynolds, R ^m,n   Glasser, D B ^m  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF VICTORIA   (Canada)

^e MINISTRY OF HEALTH   (Canada)

^f EPES Epidemiology   (Germany)

^g Grimsdyke House   (United Kingdom)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ RAYMOND POINCARÉ HOSPITAL   (France)

^j Private Urology Institute   (Germany)

^k Karnsjukhuset ^*  (Sweden)

^l Serv Urol   (Spain)

^m PFIZER INC   (United States)

ⁿ TULANE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG USE; ERECTILE DYSFUNCTION; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SENSITIVITY ANALYSIS; STROKE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; ERECTILE DYSFUNCTION; HUMANS; MALE; MEN'S HEALTH; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PURINES; RISK FACTORS; SULFONES;

EID: 38849110022     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01679.x     Document Type: Article

References (21)

1. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 2002 60 : 12 27.
2. Padma-Nathan H, Eardley I, Kloner RA et al. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002 60 : 67 90.
3. Data on File. New York, NY : Pfizer Inc, 2007.
4. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Postmarketing Safety of Sildenafil Citrate (Viagra), 2001. http://www.fda.gov/cder/consumerinfo/viagra/safety3.htm (accessed 18 December 2007).
5. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005 17 : 307 19.
6. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001 55 : 614 8.
7. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007 120 : 151 7.
8. Bacon CG, Mittleman MA, Kawachi I et al. A prospective study of risk factors for erectile dysfunction. J Urol 2006 176 : 217 21.
9. Thompson I, Tangen C, Goodman P et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005 294 : 2996 3002.
10. Muller JE, Mittleman MA, Maclure M et al. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. JAMA 1996 275 : 1405 9.
11. Moller J, Ahlbom A, Hulting J et al. Sexual activity as a trigger of myocardial infarction. A case-crossover analysis in the Stockholm Heart Epidemiology Programme (SHEEP). Heart 2001 86 : 387 90.
12. Jackson G, Montorsi P, Cheitlin MD. Cardiovascular safety of sildenafil citrate (Viagra®): an updated perspective. Urology 2006 68 : 47 60.
13. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003 57 : 597 600.
14. Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 2005 96 : 443 6.
15. Kloner RA, Jackson G, Hutter AM et al. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006 97 : 1778 84.
16. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 2006 12 : 3485 94.
17. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004 93 : 796 801.
18. Schanen JG, Iribarren C, Shahar E et al. Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study. Thorax 2005 60 : 633 8.
19. Salaycik KJ, Kelly-Hayes M, Beiser A et al. Depressive symptoms and risk of stroke: the Framingham Study. Stroke 2007 38 : 16 21.
20. Mukamal KJ, Conigrave KM, Mittleman MA et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003 348 : 109 18.
21. Pratt LA, Ford DE, Crum RM et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996 94 : 3123 9.